We demonstrated that targeting BCL9/BCL9L facilitates the antigen presentation and tumor infiltration of cDC1, as well as boosts the tumor infiltration of CD8+ T cells, thereby improving the responses to cancer immunotherapy. This evidence concerns the gene BCL9L and neoplasm.